Bibliographic details
Wang D, Bayliss S, Meads C. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: systematic review and additional economic modelling of subgroup analyses. Health Technology Assessment 2011; 15(5): 1-124
MeSH
Age Factors; Antibodies, Monoclonal /economics /therapeutic use; Antibodies, Monoclonal, Humanized; Antiviral Agents /economics /therapeutic use; Bronchiolitis, Viral /diagnosis /drug therapy /economics; Child, Preschool; Cost-Benefit Analysis; Female; Humans; Infant; Infant, Newborn; Male; Models, Economic; Palivizumab; Respiratory Syncytial Virus Infections /diagnosis /drug therapy /economics; Risk Assessment